Nivolumab-AVD improved PFS versus brentuximab vedotin-AVD in patients with advanced stage HL

N-AVD demonstrates superior efficacy and safety to Bv-AVD in older patients with advanced-stage HLПодробнее

ASCO 2023 Highlights on nivolumab in advanced stage classic Hodgkin Lymphoma: the SWOG S1826 studyПодробнее

SWOG S1826: nivolumab+AVD vs brentuximab vedotin+AVD for advanced stage Hodgkin lymphomaПодробнее

Results of SWOG S1826 Study, showing Nivo-AVD better than BV-AVD in Hodgkin's Lymphoma patientsПодробнее

ASCO23 - LBA4: SWOG S1826, Nivolumab(N)-AVD vs. Brentuximab Vedotin(BV)-AVD in Advanced Stage (A...Подробнее

Brentuximab vedotin, nivolumab, doxorubicin & dacarbazine for early stage classical Hodgkin lymphomaПодробнее

SWOG S1826: promising results with the combination of nivolumab-AVD in Hodgkin lymphomaПодробнее

Nivolumab-AVD vs brentuximab vedotin-AVD in pediatric patients with cHL: SWOG S1826 trialПодробнее

Promising results from the SWOG S1826 trial: nivo-AVD versus BV-AVD in patients with cHLПодробнее

Nivolumab + chemotherapy in previously untreated stage III or IV Hodgkin lymphomaПодробнее

Nivolumab in Advanced Hodgkin’s Lymphoma | NEJMПодробнее

NIVAHL: nivolumab and AVD in early-stage unfavorable HLПодробнее

An updated analysis of ECHELON-1: 1L brentuximab vedotin + chemotherapy in stage III/IV classical HLПодробнее

Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphomaПодробнее

Hodgkin lymphoma highlights from ASH 2023: nivo-AVD versus BV-AVD in patients with HLПодробнее

ECHELON-1 AYA subgroup results: brentuximab vedotin plus AVD vs. ABVDПодробнее

The Rationale for Exploring Brentuximab Vedotin Plus AVD in Hodgkin LymphomaПодробнее

5-year follow-up of ECHELON-1: brentuximab plus AVD versus ABVD in Hodgkin lymphomaПодробнее

SWOG S1826 Study Design Discussion in Hodgkin's Lymphoma Patients #oncology #cancer #2023Подробнее